163 related articles for article (PubMed ID: 37846495)
1. Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation.
Pai AA; Mohanan E; Panetta JC; Kulkarni UP; Illangeswaran RSS; Balakrishnan B; Jayaraman A; Edison ES; Lakshmi KM; Devasia AJ; Fouzia NA; Korula A; Abraham A; George B; Srivastava A; Mathews V; Standing JF; Balasubramanian P
Clin Pharmacol Ther; 2024 Jan; 115(1):116-125. PubMed ID: 37846495
[TBL] [Abstract][Full Text] [Related]
2. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
3. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen.
Korula A; Pn N; Devasia A; Lakshmi KM; Abraham A; Sindhuvi E; George B; Srivastava A; Mathews V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):103-108. PubMed ID: 29032269
[TBL] [Abstract][Full Text] [Related]
4. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
[TBL] [Abstract][Full Text] [Related]
5. Busulfan-Based and Treosulfan-Based Myeloablative Conditioning for Allogeneic Transplantation in Children with Thalassemia Major: a Single-Center Experience From Southern Turkey.
Aygüneş U; Karagun BS; Ay Tuncel D; Sasmaz HI; Antmen B
Exp Clin Transplant; 2023 Nov; 21(11):883-892. PubMed ID: 38140932
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Bernardo ME; Piras E; Vacca A; Giorgiani G; Zecca M; Bertaina A; Pagliara D; Contoli B; Pinto RM; Caocci G; Mastronuzzi A; La Nasa G; Locatelli F
Blood; 2012 Jul; 120(2):473-6. PubMed ID: 22645178
[TBL] [Abstract][Full Text] [Related]
7. Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Mehta P; Kapoor J; Singh A; Yadav N; Singh R; Halder R; Verma M; Agrawal N; Ahmed R; Bhurani D
Eur J Haematol; 2022 Nov; 109(5):447-457. PubMed ID: 35781894
[TBL] [Abstract][Full Text] [Related]
8. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
Bernardo ME; Zecca M; Piras E; Vacca A; Giorgiani G; Cugno C; Caocci G; Comoli P; Mastronuzzi A; Merli P; La Nasa G; Locatelli F
Br J Haematol; 2008 Nov; 143(4):548-51. PubMed ID: 18986389
[TBL] [Abstract][Full Text] [Related]
9. Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.
Kulkarni UP; Pai AA; Kavitha ML; Selvarajan S; Lionel S; Devasia AJ; Korula A; Fouzia NA; Sindhuvi E; Abraham A; Srivastava A; Mathews V; George B; Balasubramanian P
Transplant Cell Ther; 2022 Jul; 28(7):356.e1-356.e6. PubMed ID: 35550442
[TBL] [Abstract][Full Text] [Related]
10. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
[TBL] [Abstract][Full Text] [Related]
11. Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression.
Meissner B; Lang P; Bader P; Hoenig M; Müller I; Meisel R; Greil J; Sauer MG; Metzler M; Corbacioglu S; Burkhardt B; Wölfl M; Strahm B; Kafa K; Basu O; Lode HN; Gruhn B; Cario H; Ozga AK; Zimmermann M; Jarisch A; Beier R
Bone Marrow Transplant; 2024 May; 59(5):587-596. PubMed ID: 38326567
[TBL] [Abstract][Full Text] [Related]
12. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment.
Caocci G; Orofino MG; Vacca A; Piroddi A; Piras E; Addari MC; Caria R; Pilia MP; Origa R; Moi P; La Nasa G
Am J Hematol; 2017 Dec; 92(12):1303-1310. PubMed ID: 28850704
[TBL] [Abstract][Full Text] [Related]
14. Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study.
van der Stoep MYEC; Bertaina A; Moes DJAR; Algeri M; Bredius RGM; Smiers FJW; Berghuis D; Buddingh EP; Mohseny AB; Guchelaar HJ; Locatelli F; Zwaveling J; Lankester AC
Transplant Cell Ther; 2022 Feb; 28(2):99.e1-99.e7. PubMed ID: 34607071
[TBL] [Abstract][Full Text] [Related]
15. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
[TBL] [Abstract][Full Text] [Related]
18. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
[TBL] [Abstract][Full Text] [Related]
19. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Beelen DW; Stelljes M; Reményi P; Wagner-Drouet EM; Dreger P; Bethge W; Ciceri F; Stölzel F; Junghanß C; Labussiere-Wallet H; Schaefer-Eckart K; Grigoleit GU; Scheid C; Patriarca F; Rambaldi A; Niederwieser D; Hilgendorf I; Russo D; Socié G; Holler E; Glass B; Casper J; Wulf G; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; La Rocca U; Finke J; Benedetti F; Pichlmeier U; Klein A; Baumgart J; Markiewicz M
Am J Hematol; 2022 Aug; 97(8):1023-1034. PubMed ID: 35617104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
